Skip to content

Study · Observational study · n = 6,966 · 2020

3 results

Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications.

Fralick M, Gagne JJ, Patorno E, Levin R, Kesselheim AS

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research13 Mar 2020Cited by 2 (Europe PMC)

PMID32327160 (opens in a new tab)DOI10.1016/j.jval.2019.11.004 (opens in a new tab)PepBankPUB-32327160
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults prescribed dulaglutide for diabetes, 83% subsequently achieved HbA1c below 8%.

    In plain wordsIn adults prescribed dulaglutide for diabetes, 83% later had HbA1c below 8%.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableFollow-up HbA1c below 8%
    Study

    n = 6,966

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · up to 1 yearAs given in this study (human).

    Measurements

    Patients with follow-up HbA1c <8%
    83%
    dulaglutide

    Source sentences

    Summary
    The percentage of adults subsequently achieving a hemoglobin A1C below 8% ranged from 83% (dulaglutide, sitagliptin) to 71% (canagliflozin).
    2 context sentences
    Summary · context
    The primary outcome was announced in the outcomes-based contract: the percentage of adults with a follow-up hemoglobin A1C <8% up to 1 year later.
    Summary · context
    A population-based cohort study of adults newly prescribed a medication for diabetes with a publicly announced outcomes-based contract (ie, exenatide microspheres ["exenatide"], dulaglutide, or sitagliptin) was conducted.
  2. 02HumanObservational studySafety outcome

    In adults prescribed dulaglutide for diabetes, hypoglycemia occurred at 37 per 1000 person-years.

    In plain wordsIn adults prescribed dulaglutide for diabetes, low blood sugar occurred at 37 cases per 1000 person-years.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableHypoglycemia rate
    Study

    n = 6,966

    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Hypoglycemia rate
    37 per 1000 person-years
    dulaglutide

    Source sentences

    Summary
    The rate of hypoglycemia was 25 per 1000 person-years for exenatide, 37 per 1000 person-years for dulaglutide, 28 per 1000 person-years for sitagliptin, 18 per 1000 person-years for canagliflozin, and 34 per 1000 person-years for glipizide.
    3 context sentences
    Summary · context
    Thousands of adults newly filled prescriptions for exenatide (n = 5079), dulaglutide (n = 6966), sitagliptin (n = 40 752), canagliflozin (n = 16 404), or glipizide (n = 59 985).
    Summary · context
    Secondary outcomes included the percentage of patients diagnosed with hypoglycemia and the cost of a 1-month supply.
    Summary · context
    A population-based cohort study of adults newly prescribed a medication for diabetes with a publicly announced outcomes-based contract (ie, exenatide microspheres ["exenatide"], dulaglutide, or sitagliptin) was conducted.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther

    In the routine-care diabetes medication study, the cash price of a 1-month dulaglutide supply was $859.

    In plain wordsIn the study, a monthly dulaglutide supply had a cash price of $859.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableMonthly cash price
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Healthcare costs and utilization · Pharmacology

    Measurements

    Cash price of 1-month supply
    859 USD
    dulaglutide

    Source sentences

    Summary
    The cash price for a 1-month supply was $847 for exenatide, $859 for dulaglutide, $550 for sitagliptin, $608 for canagliflozin, and $14 for glipizide.
    1 context sentence
    Summary · context
    A population-based cohort study of adults newly prescribed a medication for diabetes with a publicly announced outcomes-based contract (ie, exenatide microspheres ["exenatide"], dulaglutide, or sitagliptin) was conducted.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.